Revised SPC: Vipdomet 12.5 mg/1000 mg (alogliptin/metformin) film coated tablets
SPC updated to warn that there have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including alogliptin. If bullous pemphigoid is suspected, alogliptin should be discontinued. Also interstitial nephritis added as ADR of unknown frequency.
Source:
electronic Medicines compendium